CA125 response to bevacizumab in recurrent ovarian cancer.

被引：1
|
作者：
O'Cearbhaill, R. E. [1 ]
Zhou, Q. [1 ]
Iasonos, A. [1 ]
Diaz, J. P. [1 ]
Tew, W. P. [1 ]
Hensley, M. L. [1 ]
O'Flaherty, C. [1 ]
Aghajanian, C. [1 ]
Spriggs, D. R. [1 ]
Sabbatini, P. [1 ]
机构：
[1] Mem Sloan Kettering Canc Ctr, New York, NY 10021 USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2010年 / 28卷 / 15期
关键词：
D O I：
10.1200/jco.2010.28.15_suppl.5077
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
5077
引用
下载
收藏
页数：1
相关论文
共 50 条
  • [31] CANCER ASSOCIATED ANTIGENS CA15.3 AND CA125 OVARIAN-CANCER
    LOTZNIKER, M
    BABILONTI, L
    SCARABELLI, M
    ACQUISTAPACE, L
    MORATTI, R
    PAVESI, F
    CLINICAL CHEMISTRY, 1990, 36 (06) : 1051 - 1051
  • [32] Exosomal CA125 as A Promising Biomarker for Ovarian Cancer Diagnosis
    Chen, Zhixiang
    Liang, Qianxin
    Zeng, Hua
    Zhao, Qing
    Guo, Zhaodi
    Zhong, Rihui
    Xie, Manlin
    Cai, Xiuping
    Su, Jing
    He, Zhiliang
    Zheng, Lei
    Zhao, Kewei
    JOURNAL OF CANCER, 2020, 11 (21): : 6445 - 6453
  • [33] INITIAL RESULTS WITH OVARIAN-CANCER ANTIGEN CA125
    CANNEY, PA
    MOORE, M
    JAMES, RD
    WILKINSON, PM
    BRITISH JOURNAL OF CANCER, 1984, 50 (02) : 261 - 261
  • [34] HE4 AND CA125 IN OVARIAN CANCER PATIENTS
    Kotowicz, B.
    Fuksiewicz, M.
    Kowalska, M.
    Sobiczewski, P.
    Skrzypczak, M.
    Spiewankiewicz, B.
    Kaminska, J.
    INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER, 2013, 23 (08)
  • [35] CA125 expression pattern, prognosis and correlation with serum CA125 in ovarian tumor patients - From The Danish "MALOVA" Ovarian Cancer Study
    Hogdall, Estrid V. S.
    Christensen, Lise
    Kjaer, Susanne K.
    Blaakaer, Jan
    Kjaerbye-Thygesen, Anette
    Gayther, Simon
    Jacobs, Ian J.
    Hogdall, Claus K.
    GYNECOLOGIC ONCOLOGY, 2007, 104 (03) : 508 - 515
  • [36] CA125 surveillance increases optimal resectability at secondary cytoreductive surgery for recurrent epithelial ovarian cancer
    Fleming, Nicole D.
    Cass, Liana
    Walsh, Christine S.
    Karlan, Beth Y.
    Li, Andrew J.
    GYNECOLOGIC ONCOLOGY, 2011, 121 (02) : 249 - 252
  • [37] Gynecologic Cancer InterGroup CA125 response has a high negative predictive value for CHK1 inhibitor RECIST response in recurrent ovarian cancer
    Ibanez, Kristen R.
    Donohue, Duncan
    Malys, Tyler
    Lee, Jung-Min
    SCIENTIFIC REPORTS, 2024, 14 (01):
  • [38] Predicting response of ovarian cancer to paclitaxel treatment based on trend analysis of serum CA125
    Nekulova, M
    Pecen, L
    Kalabova, R
    Simickova, M
    Topolcan, O
    Pikner, R
    Vondracek, V
    Valik, D
    CLINICAL CHEMISTRY, 2002, 48 (08) : 1364 - 1367
  • [39] TP53 autoantibody can detect CA125 screen negative ovarian cancer cases and can be elevated prior to CA125 in preclinical ovarian cancer
    Yang, Wei-Lei
    Simmons, Archana
    Lu, Zhen
    Baggerly, Keith
    Lu, Karen
    Gentry-Maharaj, Alex
    Menon, Usha
    Jacobs, Ian
    Bast, Robert C.
    CANCER RESEARCH, 2015, 75
  • [40] A research tool for elucidating the interaction between human mucin 16 (CA125) and immune cells in ovarian cancer.
    Lakatos, Kornel
    Krauledat, Petra
    Serrano, German Gonzalez
    Hansen, Peter
    Cramer, Daniel William
    Elias, Kevin
    Patankar, Manish
    Hoballah, Jawad
    CANCER RESEARCH, 2021, 81 (13)
12345